- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Organization That Addresses "Financial Toxicity" in Young Cancer Survivors Featured in Evidence-Based Oncology
The Samfund, the first and largest group created to help young adults address the costs of cancer, is featured in the current issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care. Samfund officers Samantha Watson, MBA, and Michelle S. Landwehr, MPH, address the challenges of "financial toxicity" for young adult survivors.
FOR IMMEDIATE RELEASEOCTOBER 15, 2015
PLAINSBORO, N.J.—For young adults with cancer, battling the disease can be just the beginning. Medical bills, ruined credit, and trouble finding housing can set cancer survivors back and impede their physical and emotional recovery.
Officers of The Samfund, created to help young adult cancer survivors regain their financial footing, discuss the group’s mission in the current issue of Evidence-Based Oncology, a publication of The American Journal of Managed Care. The commentary by Samantha Watson, MBA, founder and CEO, and Michelle S. Landwehr, MPH, and COO, can be found here.
“Financial toxicity” is now recognized as a common effect of cancer treatment, which makes The Samfund essential now that more than 630,000 young adults in the United States have some cancer history. The Samfund has distributed more than $1.4 million since 2004, according to Watson and Landwehr, who explore the common financial burdens that may not only prevent cancer survivors from moving on with their lives, but may also prevent them from maintaining insurance coverage essential for follow-up care.
While the Affordable Care Act has helped many young cancer survivors, they write, there is still confusion about how it works. To help survivors navigate the ACA, The Samfund has joined with Triage Cancer to present Finances 101: A Toolkit for Young Adults with Cancer. For more information, please visit the website at http://www.thesamfund.org.
Press contact: Michele Bennett for The Samfund
Phone: 203-246-7859
mailto: michele@1LCommunications.com?subject=The Samfund
Other questions may be sent to info@thesamfund.org.
The American Journal of Managed Care celebrates its 20th year in 2015 as the leading peer-reviewed journal dedicated to issues in managed care. AJMC.com distributes healthcare news to leading stakeholders across a variety of platforms. Other titles in the franchise include The American Journal of Pharmacy Benefits, which provides pharmacy and formulary decision-makers with information to improve the efficiency and health outcomes in managing pharmaceutical care, and The American Journal of Accountable Care, which publishes research and commentary on innovative healthcare delivery models facilitated by the 2010 Affordable Care Act. AJMC’s Evidence-Based series brings together stakeholder views from payers, providers, policymakers and pharmaceutical leaders in oncology and diabetes management. To order reprints of articles appearing in AJMC publications, please call (609) 716-7777, x 131.
CONTACT: Nicole Beagin (609) 716-7777 x 131
Baseline Response Rates Inform Immunotherapy Sequencing in NSCLC
December 2nd 2024Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following treatment failure and disease progression after receipt of nivolumab and pembrolizumab.
Read More
Advent of Ponatinib for Ph+ ALL Expected to Influence New Guidelines
November 29th 2024With ponatinib (Iclusig) receiving an accelerated approval from the FDA earlier this year for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), updated guidelines could be on the horizon.
Read More
US ADHD Stimulant Shortage Highlights Growing Challenges in Adult Treatment
November 27th 2024While name brands like Adderall and Vyvanse may have been recently removed from the FDA Drug Shortage Database, it's unclear if it'll last; meanwhile, many generic forms of attention-deficit/hyperactivity disorder (ADHD) medication are still in short supply.
Read More
